Luca Issi
Stock Analyst at RBC Capital
(3.68)
# 799
Out of 5,182 analysts
222
Total ratings
49.65%
Success rate
7.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Initiates: Outperform | $100 | $74.52 | +34.19% | 1 | Apr 9, 2026 | |
| QURE uniQure | Upgrades: Outperform | $11 → $35 | $17.90 | +95.53% | 8 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Sector Perform | $9 → $15 | $13.04 | +15.03% | 8 | Mar 3, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $250 → $275 | $226.66 | +21.33% | 5 | Mar 3, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $925 → $890 | $783.74 | +13.56% | 4 | Feb 27, 2026 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $22 → $26 | $29.17 | -10.85% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Sector Perform | $25 → $30 | $48.70 | -38.40% | 19 | Feb 17, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $500 → $465 | $308.51 | +50.72% | 29 | Jan 20, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $82 → $95 | $72.24 | +31.52% | 11 | Dec 17, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $52 → $80 | $73.60 | +8.70% | 11 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $9 → $27 | $6.94 | +289.05% | 6 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $10 | $7.72 | +29.53% | 3 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $57 → $28 | $24.43 | +14.61% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $85 → $8 | $12.84 | -37.69% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $42 → $50 | $50.99 | -1.94% | 15 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $19 | $8.62 | +120.42% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $30 | $18.03 | +66.44% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.25 | +344.44% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $40.95 | -56.04% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $5.63 | +255.56% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.21 | +852.38% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $9.52 | +78.57% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $9.13 | +42.39% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $9.46 | +269.98% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $53.81 | +30.10% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $55.23 | +3.20% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.89 | +38.41% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $23.94 | +221.64% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.13 | +557.28% | 5 | Aug 7, 2024 |
BridgeBio Pharma
Apr 9, 2026
Initiates: Outperform
Price Target: $100
Current: $74.52
Upside: +34.19%
uniQure
Mar 9, 2026
Upgrades: Outperform
Price Target: $11 → $35
Current: $17.90
Upside: +95.53%
Intellia Therapeutics
Mar 3, 2026
Maintains: Sector Perform
Price Target: $9 → $15
Current: $13.04
Upside: +15.03%
Ascendis Pharma
Mar 3, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $226.66
Upside: +21.33%
argenx SE
Feb 27, 2026
Maintains: Outperform
Price Target: $925 → $890
Current: $783.74
Upside: +13.56%
Beam Therapeutics
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $26
Current: $29.17
Upside: -10.85%
Moderna
Feb 17, 2026
Maintains: Sector Perform
Price Target: $25 → $30
Current: $48.70
Upside: -38.40%
Alnylam Pharmaceuticals
Jan 20, 2026
Maintains: Outperform
Price Target: $500 → $465
Current: $308.51
Upside: +50.72%
Ionis Pharmaceuticals
Dec 17, 2025
Maintains: Outperform
Price Target: $82 → $95
Current: $72.24
Upside: +31.52%
Arrowhead Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $52 → $80
Current: $73.60
Upside: +8.70%
Dec 9, 2025
Upgrades: Outperform
Price Target: $9 → $27
Current: $6.94
Upside: +289.05%
Dec 8, 2025
Maintains: Sector Perform
Price Target: $7 → $10
Current: $7.72
Upside: +29.53%
Nov 20, 2025
Downgrades: Sector Perform
Price Target: $57 → $28
Current: $24.43
Upside: +14.61%
Nov 13, 2025
Downgrades: Sector Perform
Price Target: $85 → $8
Current: $12.84
Upside: -37.69%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $42 → $50
Current: $50.99
Upside: -1.94%
Nov 7, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $8.62
Upside: +120.42%
Nov 6, 2025
Maintains: Outperform
Price Target: $23 → $30
Current: $18.03
Upside: +66.44%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $2.25
Upside: +344.44%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $40.95
Upside: -56.04%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $5.63
Upside: +255.56%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.21
Upside: +852.38%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $9.52
Upside: +78.57%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $9.13
Upside: +42.39%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $9.46
Upside: +269.98%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $53.81
Upside: +30.10%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $55.23
Upside: +3.20%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.89
Upside: +38.41%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $23.94
Upside: +221.64%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $2.13
Upside: +557.28%